Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Z. DeFilipp*, R. Ancheta, Y. Liu, Z.H. Hu, R.P. Gale, D. Snyder, H.C. Schouten, M. Kalaycio, G.C. Hildebrandt, C. Ustun, A. Daly, S. Ganguly, Y. Inamoto, M. Litzow, J. Szer, M.L. Savoie, N. Hossain, M.A. Kharfan-Dabaja, M. Hamadani, R. ReshefA. Bajel, K.R. Schultz, S. Gadalla, A. Gerds, J. Liesveld, M.B. Juckett, R. Kamble, S. Hashmi, H. Abdel-Azim, M. Solh, U. Bacher, H. Lazarus, R. Olsson, J.Y. Cahn, M.R. Grunwald, B.N. Savani, J. Yared, J.M. Rowe, J. Cerny, N.A. Chaudhri, M. Aljurf, A. Beitinjaneh, S. Seo, T. Nishihori, J.W. Hsu, M. Ramanathan, E. Alyea, U. Popat, R. Sobecks, W. Saber

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)

Abstract

It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myelogenous leukemia (CML). In this registry study, we analyzed clinical outcomes of 390 adult patients with CML who underwent transplantation between 2007 and 2014 and received maintenance TKI following HCT (n = 89) compared with no TKI maintenance (n = 301), as reported to the Center for International Blood and Marrow Transplant Research. All patients received TKI therapy before HCT. The majority of patients had a disease status of first chronic phase at HCT (n = 240; 62%). The study was conducted as a landmark analysis, excluding patients who died, relapsed, had chronic graft-versus-host disease, or were censored before day +100 following HCT. Of the 89 patients who received TKI maintenance, 77 (87%) received a single TKI and the other 12 (13%) received multiple sequential TKIs. The most common TKIs used for maintenance were dasatinib (n = 50), imatinib (n = 27), and nilotinib (n = 27). As measured from day +100, the adjusted estimates for 5-year relapse (maintenance, 35% versus no maintenance, 26%; P = .11), leukemia-free survival (maintenance, 42% versus no maintenance, 44%; P = .65), or overall survival (maintenance, 61% versus no maintenance, 57%; P = .61) did not differ significantly between patients receiving TKI maintenance or no maintenance. These results remained unchanged in multivariate analysis and were not modified by disease status before transplantation. In conclusion, our data from this day +100 landmark analysis do not demonstrate a significant impact of maintenance TKI therapy on clinical outcomes. The optimal approach to TKI administration in the post-transplantation setting in patients with CML remains undetermined. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
Original languageEnglish
Pages (from-to)472-479
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume26
Issue number3
DOIs
Publication statusPublished - 1 Mar 2020

Keywords

  • allogeneic hematopoietic cell transplantation
  • chronic myelogenous leukemia
  • chronic myeloid-leukemia
  • imatinib
  • maintenance
  • nilotinib prophylaxis
  • outcomes
  • therapy
  • tyrosine kinase inhibitor
  • NILOTINIB PROPHYLAXIS
  • Tyrosine kinase inhibitor
  • Chronic myelogenous leukemia
  • Maintenance
  • CHRONIC MYELOID-LEUKEMIA
  • THERAPY
  • Allogeneic hematopoietic cell transplantation
  • IMATINIB
  • OUTCOMES

Cite this